Cargando…

Reperfusion Therapies for Acute Ischemic Stroke in COVID-19 Patients: A Nationwide Multi-Center Study

(1) Background: Acute ischemic stroke (AIS) is a possible complication of the coronavirus disease 2019 (COVID-19). Safety and efficacy data on reperfusion therapies (RT)—intravenous thrombolysis and endovascular treatment (EVT)—in stroke patients with COVID-19 is lacking. (2) Methods: We performed a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jurkevičienė, Justina, Vaišvilas, Mantas, Masiliūnas, Rytis, Matijošaitis, Vaidas, Vaitkus, Antanas, Geštautaitė, Dovilė, Taroza, Saulius, Puzinas, Paulius, Galvanauskaitė, Erika, Jatužis, Dalius, Vilionskis, Aleksandras
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181080/
https://www.ncbi.nlm.nih.gov/pubmed/35683393
http://dx.doi.org/10.3390/jcm11113004
_version_ 1784723679426379776
author Jurkevičienė, Justina
Vaišvilas, Mantas
Masiliūnas, Rytis
Matijošaitis, Vaidas
Vaitkus, Antanas
Geštautaitė, Dovilė
Taroza, Saulius
Puzinas, Paulius
Galvanauskaitė, Erika
Jatužis, Dalius
Vilionskis, Aleksandras
author_facet Jurkevičienė, Justina
Vaišvilas, Mantas
Masiliūnas, Rytis
Matijošaitis, Vaidas
Vaitkus, Antanas
Geštautaitė, Dovilė
Taroza, Saulius
Puzinas, Paulius
Galvanauskaitė, Erika
Jatužis, Dalius
Vilionskis, Aleksandras
author_sort Jurkevičienė, Justina
collection PubMed
description (1) Background: Acute ischemic stroke (AIS) is a possible complication of the coronavirus disease 2019 (COVID-19). Safety and efficacy data on reperfusion therapies (RT)—intravenous thrombolysis and endovascular treatment (EVT)—in stroke patients with COVID-19 is lacking. (2) Methods: We performed a retrospective nationwide multi-center pair-matched analysis of COVID-19 patients with AIS who underwent RT. We included adult COVID-19 patients with AIS who were treated with RT between 16 March 2020 and 30 June 2021. All subjects were paired with non-infected controls, matched for age, sex, stroke arterial vascular territory, and RT modality. The primary outcome measure was a favorable functional outcome defined by the modified Rankin scale (mRS 0–2). (3) Results: Thirty-one subjects and thirty-one matched controls were included. The median baseline National Institutes of Health Stroke Scale (NIHSS) score was higher in the COVID-19 group (16 vs. 12, p = 0.028). Rates of ischemic changes and symptomatic intracerebral hemorrhages did not differ significantly between the two groups at 24 h after RT. The median NIHSS 24 h after reperfusion remained significantly higher in the COVID-19 group (16 vs. 5, p = 0.003). MRS 0–2 at discharge was significantly less common in COVID-19 patients (22.6% vs. 51.8%, p = 0.018). Three-month mortality was 54.8% in the COVID-19 group versus 12.9% in controls (p = 0.001). (4) Conclusion: Reperfusion therapies on AIS in COVID-19 patients appear to be safe; however, functional outcomes are significantly worse, and 3-month mortality is higher.
format Online
Article
Text
id pubmed-9181080
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91810802022-06-10 Reperfusion Therapies for Acute Ischemic Stroke in COVID-19 Patients: A Nationwide Multi-Center Study Jurkevičienė, Justina Vaišvilas, Mantas Masiliūnas, Rytis Matijošaitis, Vaidas Vaitkus, Antanas Geštautaitė, Dovilė Taroza, Saulius Puzinas, Paulius Galvanauskaitė, Erika Jatužis, Dalius Vilionskis, Aleksandras J Clin Med Article (1) Background: Acute ischemic stroke (AIS) is a possible complication of the coronavirus disease 2019 (COVID-19). Safety and efficacy data on reperfusion therapies (RT)—intravenous thrombolysis and endovascular treatment (EVT)—in stroke patients with COVID-19 is lacking. (2) Methods: We performed a retrospective nationwide multi-center pair-matched analysis of COVID-19 patients with AIS who underwent RT. We included adult COVID-19 patients with AIS who were treated with RT between 16 March 2020 and 30 June 2021. All subjects were paired with non-infected controls, matched for age, sex, stroke arterial vascular territory, and RT modality. The primary outcome measure was a favorable functional outcome defined by the modified Rankin scale (mRS 0–2). (3) Results: Thirty-one subjects and thirty-one matched controls were included. The median baseline National Institutes of Health Stroke Scale (NIHSS) score was higher in the COVID-19 group (16 vs. 12, p = 0.028). Rates of ischemic changes and symptomatic intracerebral hemorrhages did not differ significantly between the two groups at 24 h after RT. The median NIHSS 24 h after reperfusion remained significantly higher in the COVID-19 group (16 vs. 5, p = 0.003). MRS 0–2 at discharge was significantly less common in COVID-19 patients (22.6% vs. 51.8%, p = 0.018). Three-month mortality was 54.8% in the COVID-19 group versus 12.9% in controls (p = 0.001). (4) Conclusion: Reperfusion therapies on AIS in COVID-19 patients appear to be safe; however, functional outcomes are significantly worse, and 3-month mortality is higher. MDPI 2022-05-26 /pmc/articles/PMC9181080/ /pubmed/35683393 http://dx.doi.org/10.3390/jcm11113004 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jurkevičienė, Justina
Vaišvilas, Mantas
Masiliūnas, Rytis
Matijošaitis, Vaidas
Vaitkus, Antanas
Geštautaitė, Dovilė
Taroza, Saulius
Puzinas, Paulius
Galvanauskaitė, Erika
Jatužis, Dalius
Vilionskis, Aleksandras
Reperfusion Therapies for Acute Ischemic Stroke in COVID-19 Patients: A Nationwide Multi-Center Study
title Reperfusion Therapies for Acute Ischemic Stroke in COVID-19 Patients: A Nationwide Multi-Center Study
title_full Reperfusion Therapies for Acute Ischemic Stroke in COVID-19 Patients: A Nationwide Multi-Center Study
title_fullStr Reperfusion Therapies for Acute Ischemic Stroke in COVID-19 Patients: A Nationwide Multi-Center Study
title_full_unstemmed Reperfusion Therapies for Acute Ischemic Stroke in COVID-19 Patients: A Nationwide Multi-Center Study
title_short Reperfusion Therapies for Acute Ischemic Stroke in COVID-19 Patients: A Nationwide Multi-Center Study
title_sort reperfusion therapies for acute ischemic stroke in covid-19 patients: a nationwide multi-center study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181080/
https://www.ncbi.nlm.nih.gov/pubmed/35683393
http://dx.doi.org/10.3390/jcm11113004
work_keys_str_mv AT jurkevicienejustina reperfusiontherapiesforacuteischemicstrokeincovid19patientsanationwidemulticenterstudy
AT vaisvilasmantas reperfusiontherapiesforacuteischemicstrokeincovid19patientsanationwidemulticenterstudy
AT masiliunasrytis reperfusiontherapiesforacuteischemicstrokeincovid19patientsanationwidemulticenterstudy
AT matijosaitisvaidas reperfusiontherapiesforacuteischemicstrokeincovid19patientsanationwidemulticenterstudy
AT vaitkusantanas reperfusiontherapiesforacuteischemicstrokeincovid19patientsanationwidemulticenterstudy
AT gestautaitedovile reperfusiontherapiesforacuteischemicstrokeincovid19patientsanationwidemulticenterstudy
AT tarozasaulius reperfusiontherapiesforacuteischemicstrokeincovid19patientsanationwidemulticenterstudy
AT puzinaspaulius reperfusiontherapiesforacuteischemicstrokeincovid19patientsanationwidemulticenterstudy
AT galvanauskaiteerika reperfusiontherapiesforacuteischemicstrokeincovid19patientsanationwidemulticenterstudy
AT jatuzisdalius reperfusiontherapiesforacuteischemicstrokeincovid19patientsanationwidemulticenterstudy
AT vilionskisaleksandras reperfusiontherapiesforacuteischemicstrokeincovid19patientsanationwidemulticenterstudy